lenvatinib
lenvatinib: 46 clinical trials tracked.
lenvatinib evidence translation
What we can confirm
46 tracked trials
What it means
What to watch
Prepared research question
What is verified about lenvatinib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 4 study sponsors
Related indications
Clinical Trial Registry Records (46)showing 10 most recent
A Clinical Study of Iparomlimab and Tuvonralimab Combined With Lenvatinib, Radiotherapy, and Hepatic Arterial Infusion Chemotherapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Primary endpoint: Progression-Free Survival (PFS)
A Randomized, Open-Label, Phase 3 Study to Investigate the Efficacy and Safety of BGB-B2033 Compared With Investigator Choice of Sorafenib or Lenvatinib in Patients With Hepatocellular Carcinoma That Progressed Upon Prior Systemic Treatment
Primary endpoint: Overall Survival (OS)
A Multicenter Single-arm Phase 2 Study of Pembrolizumab and Lenvatinib in Previously Treated Inoperable or Advanced Anal Squamous Cell Cancer
Primary endpoint: Objective response rate of pembrolizumab and lenvatinib combination
Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]
Primary endpoint: Progression-free survival (PFS)
A Multicenter, Open-label, Phase 3 Extension Study to Evaluate the Long-term Efficacy and Safety in Participants Who Are Currently on Treatment in a Belzutifan Study (LITESPARK-043)
Primary endpoint: Cohort A and Cohort B: Overall Survival (OS)
A Multicenter, Open-Label, Randomized, Phase II Study of Lenvatinib Plus Pembrolizumab With or Without Branched-Chain Amino Acids in Unresectable Hepatocellular Carcinoma
Primary endpoint: Progression-Free Survival (PFS)
A Phase II Study of STRIDE (Durvalumab + Tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Primary endpoint: Progression-free Survival using RECIST 1.1
A Pilot Study of Lenvatinib in Combination With Pembrolizumab in HPV-associated Recurrent Respiratory Papillomatosis Patients
Primary endpoint: Objective Response Rate (ORR)
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer
Primary endpoint: Number of Participants with Adverse Events (AE)s
A Phase Ib/II Trial of Lenvatinib Plus Pembrolizumab Plus Fulvestrant in ER-positive/ HER2- Negative Metastatic Breast Cancer
Primary endpoint: The number of adverse events and dose-limiting toxicities to find the Recommended Phase 2 Dose (RP2D)